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Abstract
Background: CP-31398 is a small molecule that has been reported to stabilize the DNA-binding
core domain of the human tumor suppressor protein p53 in vitro. The compound was also reported
to function as a potential anti-cancer drug by rescuing the DNA-binding activity and, consequently,
the transcription activation function of mutant p53 protein in mammalian tissue culture cells and in
mice.
Results: We performed a series of gene expression experiments to test the activity of CP-31398
in yeast and in human cell cultures. With these cell-based assays, we were unable to detect any
specific stimulation of mutant p53 activity by this compound. Concentrations of CP-31398 that
were reported to be active in the published work were highly toxic to the human H1299 lung
carcinoma and Saos-2 cell lines in our experiments.
Conclusion: In our experiments, the small molecule CP-31398 was unable to reactivate mutant
p53 protein. The results of our in vivo experiments are in agreement with the recently published
biochemical analysis of CP-31398 showing that this molecule does not bind p53 as previously
claimed, but intercalates into DNA.
Background
The tumor suppressor protein p53 protects organisms
from malignancy by either inducing programmed cell
death or by arresting the cell cycle in response to cellular
stress. The intracellular concentration of p53 is tightly reg-
ulated at the posttranslational level and the protein is very
unstable under physiological conditions. Upon stress,
p53 is stabilized and can act as a potent transcription fac-
tor that activates a plethora of downstream target genes
[1,2]. The p53 target genes can be grouped into classes
according to their effect on a cell. One class is represented
by p21CIP, a cyclin dependent kinase inhibitor that is a
potent inhibitor of the cell cycle. Another class of p53 tar-
get genes, of which bax is the most known representative,
mediates p53-induced apoptosis. Other p53 target genes
prevent the process of angiogenesis [2].
Not surprisingly, p53 is inactivated in a wide variety of
human cancers [1,3]. Most mutations found in cancers are
mis-sense mutations mapping to the central core domain
of p53, which confers sequence-specific DNA binding
activity to the protein. These mutations can cause destabi-
lization of the core domain and loss of the DNA binding
function. Thus, most mutant p53 proteins lack the ability
to bind the DNA control elements of their target genes
and fail to activate their expression. As a consequence,
cells lacking functional p53 are unable to arrest the cell
cycle or to undergo apoptosis in response to genotoxic
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in cancer development and in resistance to treatment,
there has been much interest in the search of means and
molecules to reactivate mutant forms of p53 [4-9].
A report by Foster et al. [7] generated special interest since
it reported the discovery of a class of small molecules that
was able to stabilize the p53 core domain. Not only were
these compounds reported to stabilize the active confor-
mation of wild type p53 but they were also shown to sta-
bilize mutant p53 forms and enable them to activate
transcription of p53 target genes. While the initial screen-
ing was conducted by an in vitro assay, activity of these
compounds was subsequently confirmed in cell culture
experiments and in a xenograft tumor mouse model [7].
One of their compounds, termed CP-31398, was reported
to increase reporter gene activation by mutant p53 pro-
teins about tenfold in the human p53-null lung carci-
noma cell line H1299.
We tested CP-31398 in a yeast cell-based assay and in
human tissue culture cells. We could not detect any reac-
tivation of mutant p53 in these cellular assays. Our results
are in agreement with, and provide support to the results
obtained by Rippin et al. [10], which indicate that CP-
31398 intercalates with DNA rather than binding p53.
Results
The yeast Saccharomyces cerevisiae does not contain p53
homologous proteins. However, it has been demon-
strated that p53 expressed in yeast can function as a potent
transcriptional activator of artificial genes bearing its spe-
cific recognition sequence [11]. To test different mutant
forms of p53 and the potential effect of various molecules
on the activity of such mutants, we constructed a yeast
strain carrying an integrated bi-directional reporter gene
construct in which a single p53 binding site from the
human p21CIP1 promoter [12] was inserted between the
divergent HIS3 and lacZ genes (figure 1A). The p53-
dependent expression of the yeast marker gene HIS3
allows growth selection on media lacking histidine and
containing 3-amino-triazole (3-AT), which is a competi-
tive inhibitor of the HIS3 gene product. The p53-depend-
ent activation of this reporter gene is convenient for
library screening, while expression of the bacterial lacZ
gene allows verification and quantitation of the transcrip-
tional activity of the various p53 forms and putative
modulators.
Transformation of this strain with an episomal plasmid
expressing human wild type p53 led to activation of the
integrated lacZ and HIS3 reporter genes, which resulted in
increased β-galactosidase activity (figure 1B) and cell
growth on plates lacking histidine and containing 20 mM
3-AT (figure 1C). In contrast, expression of three mutant
forms of p53 [1] with point mutations in their DNA-bind-
ing domain that completely abolish sequence-specific
DNA-binding activity (p53R175H, p53R248W,
p53R273H) did not activate transcription of the reporter
genes (figure 1B and 1C, and data not shown). Expression
of mutant forms that retain some DNA-binding activity in
vitro and in mammalian cells [13] led to reduction of
reporter gene expression compared to wild type p53 (fig-
ure 1B). All p53 variants were expressed to comparable
levels, as verified by western blot analysis (data not
shown).
Thus, the results of these transcriptional assays, taken
together with published results of experiments performed
in mammalian cells, indicate that the relative transcrip-
tional activity of wild type p53 and the tested derivatives
is comparable in yeast and in human cells.
Since lack of p53 function plays such a central role in can-
cer development and in resistance to chemotherapeutic
treatment, many efforts have been directed towards trying
to reactivate mutant forms of p53 [4-9,14]. The report by
Foster et al. [7] generated special interest since it presented
the discovery of a small molecule (CP-31398) that was
able to stabilize the core domain of p53 in vitro. In addi-
tion, this compound was reported to enable some other-
wise silent p53 mutants to activate transcription from
target gene promoters in cell culture experiments.
We tested the effect of CP-31398 on human p53 activity
in our p53-responsive yeast strain. Yeast cells expressing
either wild type p53 or the mutant p53R173A were grown
in media containing increasing concentrations of CP-
31398. Activation of transcription of the p53-dependent
reporter gene was assessed by measuring β-galactosidase
activity in extracts from these cells (figure 2). No signifi-
cant difference in lacZ reporter gene expression was
observed between untreated cells and cells that were incu-
bated with increasing concentrations of the compound.
Very high concentrations of CP-31398 (500 µg/ml)
reduced reporter gene activity, both in the case of wild
type p53 expression and in the case of p5R173A expres-
sion. Results of growth assays on selective plates to indi-
rectly measure HIS3 expression paralleled our data from
the lacZ experiments (data not shown).
Since these negative results regarding the lack of expected
effects of CP-31398 on p53 could be due to our assay sys-
tem in yeast, we tested CP-31398 in experiments with
human tissue culture cells. We transfected the human
p53-null H1299 lung carcinoma cell line that was also
used for some of the experiments described by Foster et al.
[7] with plasmid DNA expressing either human wild type
p53 or the p53R173A mutant together with a reporter
plasmid carrying a p53-responsive luciferase gene [12].Page 2 of 9
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Human p53 protein activates transcription from a reporter construct in Saccharomyces cerevisiae. (A) Schematic representation 
of our yeast reporter construct integrated into our yeast strain. The black circle represents a single p53 responsive element 
from the human p21 promoter. (B) β-galactosidase assay to measure activation of the lacZ reporter gene. Wild type p53 and 
the indicated point mutant variants were transformed into the p53 responsive reporter strain and β-galactosidase activity in 
solution was determined. The activity of wild type p53 was arbitrarily set to 100%. p53R282W and p53V173A showed about 
40% of activation compared to wild type p53. No activation of the reporter gene was detected in yeast cells containing the 
other point mutant variants. Average and standard deviation were determined from three independent experiments. (C) 
Growth on selective plates containing 20 mM 3-AT depends on expression of the HIS3 reporter gene and correlates with the 
activation of the lacZ reporter gene. Control plates consist of standard drop-out plates lacking the corresponding growth 
marker without 3-AT. Growth under selective conditions was dependent on activation of the p53 dependent reporter gene.Page 3 of 9
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tions that were shown to be effective by Foster et al. (5–20
µg/ml and higher concentrations), reporter gene signals
decreased and massive cell death was observed (figure 3A
and data not shown). Lower concentrations that showed
no obvious toxicity to the cells had no significant effect on
reporter gene activity. We observed very similar effects
when we performed corresponding experiments in the
osteosarcoma cell line Saos-2 (p53 null cell line) (data not
shown).
Cell death and decreased reporter gene activity was not
dependent on the expression of p53 since treatment with
CP-31398 of the same cell lines expressing the unrelated
activator GAL4-VP16 co-transfected with the respective
reporter construct caused similar toxicity and lower
reporter gene activity (figure 3B).
We next tested whether CP-31398 might have an effect on
endogenous wild type p53 in the human cell line HeLa.
These cells express wild type p53 protein, but p53 levels
are low because of the presence of the viral HPV E6 pro-
tein, which targets p53 for degradation [15]. We trans-
fected HeLa cells with the same p53-dependent luciferase
reporter construct that was used with the other cell lines
and treated the cells with increasing concentrations of CP-
31398 (figure 4). To our surprise, there was a strong
increase in reporter gene activation. When we expressed
additional human wild type p53 from a transfection plas-
mid, the signal increased even more (data not shown). In
contrast to the previous effect on other cell lines described
above, we did not observe any significant cell death in the
case of HeLa.
We subjected extracts from HeLa cells treated with CP-
31398 to western blot analysis. The p53 signals correlated
with increasing CP-31398 concentrations, whereas the
actin control signals did not (figure 5A). These results are
consistent with a classical response to genotoxic stress by
compounds causing stabilization of p53 [16].
Treatment with the p53 stabilizing compound CP-31398 shows no effect on reporter gene activity in yeastFigure 2
Treatment with the p53 stabilizing compound CP-31398 shows no effect on reporter gene activity in yeast. Yeast cells express-
ing wild type p53 (lanes 1–5), p53V173A (lanes 6–10) or empty vector (-, lanes 11–15, white bars) were incubated with the 
concentrations of CP-31398 indicated (0–500 µg/ml) and expression of β-galactosidase was determined. β-galactosidase activ-
ity of wild type p53 without CP-31398 treatment was arbitrarily set to 100%. Yeast cells were treated with CP-31398 for 16 
hours.Page 4 of 9
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Treatment of H1299 lung carcinoma cells with CP-31398 provokes massive cell death and p53 independent decline of luci-
ferase reporter gene activity. (A) H1299 cells were transfected with expression constructs for wild type p53 (lanes 1–3) and 
p53V173A (lanes 4–6). All the samples were cotransfected with a p53-responsive luciferase reporter (p21 luciferase, containing 
a single p53 responsive p53 binding site from the human p21 promoter, termed WWP-luc, see material and methods) and a 
constitutive reference β-galactosidase construct (CMV-lacZ) for normalization. These cells were subsequently incubated with 
0, 10, 15 µg/ml CP-31398 respectively and relative luciferase activities were determined. (B) H1299 cells were transfected with 
an expression construct for the synthetic activator GAL4-VP16. All samples were cotransfected with a gal4p responsive luci-
ferase reporter (UASG luciferase) and a reference β-galactosidase plasmid (CMV-lacZ) for normalization. The control cells 
were transfected with CMV-lacZ and UASG luciferase only. These cells were subsequently incubated with 0, 10 and 15 µg/ml 
CP-31398 and relative luciferase activities were determined. The cells were treated with CP-31398 for 16 hours.Page 5 of 9
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treatment with increasing concentration of daunorubicin,
a known anticancer agent that is highly cytotoxic by a
number of proposed mechanisms – intercalation into
DNA among them [17]. We found, as expected, that dau-
norubicin treatment led to a progressive stabilization of
p53 in HeLa cells comparable to the response when cells
were treated with CP-31398 (figure 5B).
Discussion
We assessed the proposed p53 stabilizing action of CP-
31398 in yeast cells and in human cells. CP-31398, a com-
pound isolated in an antibody-based in vitro screen, was
reported to stabilize the p53 DNA-binding core domain
and to reactivate mutant p53 in vivo [7]. We were unable
to detect any effect of CP-31398 on p53-dependent
reporter gene activation by a mutant form of human p53
neither in human cells nor in yeast cells. In our hands, CP-
31398 did not stabilize mutant p53 proteins so as to show
differences in activation of p53-dependent reporter genes
in yeast and in mammalian cells. In addition, concentra-
tions that were shown to be effective in cell culture by Fos-
ter et al. [7] led to extensive cell death. Most importantly,
such cell death was independent of p53 expression.
The p53 protein expressed within yeast cells functions as
a potent transcriptional activator. Reconstitution of tran-
scriptional activation by p53 in a heterologous, yet cellu-
lar system such as a yeast cell should be suitable to assess
DNA-binding and transcriptional activation activity
regardless of posttranslational modifications and other
influences that are inevitable when p53 is studied in the
context of its regulatory network in mammalian cells. It
has been proposed that such posttranslational
Treatment of HeLa cervical carcinoma cells with CP-31398 leads to p53 dependent induction of the luciferase reporterFigure 4
Treatment of HeLa cervical carcinoma cells with CP-31398 leads to p53 dependent induction of the luciferase reporter. HeLa 
cells were transfected with a p53 responsive reporter gene (WWP-luc) and a reference β-galactosidase plasmid (CMV-lacZ) 
for normalization. Control cells were transfected with CMV-lacZ alone. The cells were subsequently incubated with CP-31398 
(0–10 µg/ml) and relative luciferase activities were determined. Cells were treated for 16 hours.Page 6 of 9
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vate the latent DNA binding activity of p53 by allosteric
mechanisms [18]. However, more recent in vivo and in
vitro studies question whether DNA binding itself is regu-
lated at all and suggest that induction of p53 activity pri-
marily occurs at the level of increasing protein
concentration within the nucleus [16,19,20]. The evident
p53 activity in yeast cells, in which the proposed mamma-
lian-specific p53 modifying enzymes are missing, seems
to be more readily consistent with the conclusions of such
studies. With our system in yeast, we should be able to
detect stabilization of the p53 core domain as long as this
leads to increased binding of p53 to its specific DNA rec-
ognition sequence and subsequent activation of reporter
gene expression. Therefore, our yeast system provides a
convenient means to screen compound libraries for iden-
tifying molecules that can reactivate mutant p53 proteins
in a cellular environment. Thanks to the easy genetic mal-
leability of yeast and the lack of endogenous p53-related
pathways, cellular screens with this organism should
allow not only identification of compounds that can per-
meate cellular membranes and be active in an intracellu-
lar environment but also rapid exclusion of molecules
that are not specific for the chosen target.
In contrast to the results obtained with the exogenous
expression of wild type p53 in yeast cells or with the
H1299 and Saos-2 human cells, we observed a strong
increase in wild type p53-dependent reporter gene activa-
tion in HeLa cells. These cells showed no apparent cell
death after treatment with CP-31398. Wang et al. [21]
reported stabilization of wild type p53 and an increase in
p53 levels in other cell lines. These observations are con-
sistent with the results we obtained in HeLa cells. These
authors also reported that ubiquitination and degradation
of wild type p53 is blocked by CP-31398. This effect seems
to be specific to mdm2-mediated p53 degradation since
HPV (human papilloma virus) E6-mediated degradation
of p53 was unaffected. We do not know why we do not see
any stabilization of exogenous p53 in H1299 or Saos-2
cells, but it is possible that unspecific toxicity induced by
CP-31398 masks the increasing p53-dependent reporter
signal. While these results indicate that CP-31398 might
stabilize wild type p53, they do not explain the mecha-
nism. Direct interaction and stabilization of p53 is not
excluded. However, other explanations seem plausible.
Stabilization of the core domain structure by CP-31398 as
proposed in the original article should presumably have
no effect on p53 protein levels. But p53 levels increase
after treatment with CP-31398. Such a response is in line
with a classical stabilisation of p53 after genotoxic stress.
In contrast, Wang et al. reported that no serine 15 or 20
phosphorylation was detected in their cells after treatment
with CP-31398. Interaction with mdm2 was unaffected,
but p53 degradation was nevertheless blocked [21].
Therefore, it remains unclear by which mechanism CP-
31398 stabilizes p53; it seems unlikely that core domain
stability and DNA binding are influenced by CP-31398
directly. It is interesting to note that CP-31398 can
intercalate into DNA as reported by Rippin et al. [10]. This
intercalation is probably toxic to the cell and likely
induces a classical p53 response, similar to the known p53
inducer daunorubicin.
Our results strongly suggest a classical p53 stabilization
through reduced degradation due to genotoxic effects
caused by CP-31398. In fact, wild type p53 levels changed
quite dramatically in HeLa cells, which are resitant to the
apoptotic effects of p53, whereas the other human cell
lines did not survive the treatment, probably because they
underwent apoptosis in response to CP-31398 [22]. In
support to this interpretation, our control substance dau-
norubicin showed very similar and expected results as
those obtained with CP-31398.
Conclusions
In contrast to the results reported by Foster et al. [7], we
did not detect any stimulation of mutant p53 activity in
vivo by CP-31398, a potential anti-cancer compound.
Concentrations of CP-31398 that were reported to be
active in the published work were highly toxic to human
cells in our experiments. The results of our in vivo experi-
ments are in agreement with the recently published bio-
chemical analysis of CP-31398, which shows that this
molecule does not bind p53 as previously claimed, but
rather intercalates into DNA.
Western Blot analysis of HeLa cells treated with CP-31398 and dau orubicinFigure 5
Western Blot analysis of HeLa cells treated with CP-31398 
and daunorubicin. (A) HeLa cells were treated with increas-
ing concentrations of CP-31398 and protein extracts were 
subjected to SDS-PAGE and subsequent detection with an 
anti-p53 antibody (DO-1). (B) HeLa cells were treated with 
the established p53 inducing agent daunorubicin. Protein 
extracts were subjected to SDS-PAGE and subsequent 
detection with an anti-p53 antibody (DO-1). Expression of 
actin is detected as a loading control in experiments 5A and 
B.Page 7 of 9
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Yeast strains
The yeast strain used in our experiments is a derivative of
the S. cerevisiae strain JPY5 [23] (MAT ura3-52 his3∆200
leu2∆1 trp1∆63 lys2∆385). The p53 responsive yeast strain
was constructed by integration of the reporter construct
described in the result section and in figure 1A into the
HIS3 locus by homologous recombination. The integrat-
ing p21 reporter plasmid was linearized with AflII that
cuts in the 3' untranslated region (3'UTR) of the S. cerevi-
siae HIS3 gene.
Yeast growth and manipulations
Yeast genetic techniques and media were as described in
[24]. For selection of plasmids, dropout media containing
all except the specified amino acids were used. Yeast
transformation was performed by the lithium acetate pro-
cedure [25].
Recombinant plasmids
All p53 forms tested in yeast were expressed from the vec-
tor pGAD424 (Clontech, Inc). Wild type p53 was sub-
cloned from a mammalian expression vector with primers
containing HinDIII restriction sites by polymerase chain
reaction (PCR). The PCR product was introduced into the
HinDIII sites of pGAD424, removing the GAL4AD ORF
from pGAD424. All the point mutant p53 variants were
generated by assembled PCR with mismatched primer
pairs and subsequent cloning into pGAD424 analogous
to wild type p53. The yeast reporter plasmid was derived
from pDE96 (yeast integrating plasmid, bi-directional
HIS3, lacZ) [26] by introduction of a hybridised double
stranded oligo containing the p53 responsive element
from the p21CIP1 promoter (p21_sense_SalI 5'-TCG AGC
CGT CAG GAA CAT GTC CCA ACA TGT TGA GCT G-3'
and p21_anti_XbaI 5'-CTA GCA GCT CAA CAT GTT GGG
ACA TGT TCC TGA CGG C-3') into the XbaI and SalI sites
of the vector backbone. The plasmid WWP-luc is
described in [12].
The mammalian p53 expression plasmids were con-
structed by subcloning the HinDIII p53 fragments from
the yeast expression vectors into the GAL4 expression
plasmid pSCETV-GAL4(1-93)RV, this resulted in p53
expression under the control of the CMV promoter. The
mammalian GAL4 dependent reporter Gal5-luc contains
five GAL4 responsive binding sites in front of the luci-
ferase cassette [27]. Gal4-VP16 is described elsewhere
[28].
Yeast β-galactosidase assay
Yeast β-galactosidase assays in solution using permeabi-
lized cells were performed as described in [24]. Activity
was normalized to the number of cells assayed.
Mammalian cell culture
Cells were obtained from ATCC (American Type Culture
Collection, Manassas, Virginia, USA) and cultured accord-
ing to the recommendations of ATCC.
Transient transfection and luciferase assays
We used Polyfect® transfection reagent (Qiagen, Inc)
according to manufacturers recommendations for trans-
fection of all cell lines. Cells for luciferase assays and west-
ern blotting were harvested by scraping 48 hours after
transfection and subjected to three freeze thaw cycles in
100 mM potassium phosphate pH 7.8 1 mM dithiothrei-
tol buffer. Supernatants were clarified by centrifugation (5
min, 13000 rpm) and resuspended in 100 µl extraction
buffer. 10 µl of extract was mixed with 100 µl luciferase
assay solution (Promega) and analyzed in a luminometer
(EG&G Berthold Lumat LB 9507). β-galactosidase assays
were performed according to standard methods using 50
µl of the extract and luciferase units were normalized
according to β-galactosidase values. All measurements
were performed from at least two independent transfec-
tions experiments.
Western blot analysis and antibodies
Protein extracts were prepared as described above. Pro-
teins were separated by SDS-PAGE, electrophoretically
transferred to nitrocellulose membranes, and western
blotting was performed according to standard procedures.
Anti-p53 antibody DO-1 (Santa Cruz Biotechnology, Inc)
reacts with an amino terminal epitope mapping between
amino acid residues 11–25 of wild type and mutant p53.
Anti-actin antibody (I-19; Santa Cruz Biotechnology, Inc)
is an affinity purified goat polyclonal antibody raised
against a peptide mapping to the carboxy terminus of
human actin.
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